Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nontuberculous mycobacteria

D E Griffith1

  • 1University of Texas Health Center, Tyler, Center for Pulmonary Infectious Disease Control 75710, USA.

Current Opinion in Pulmonary Medicine
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When is a non-tuberculous mycobacterial infection a pulmonary disease?

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2016
Same author

Pulmonary non-tuberculous mycobacterial infections.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2010
Same author

Treatment of isoniazid-resistant tuberculosis in southeastern Texas.

Chest·2001
Same author

The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages.

The Journal of antimicrobial chemotherapy·2001
Same author

T cells enhance production of IL-18 by monocytes in response to an intracellular pathogen.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Nontuberculous mycobacteria (NTM) infections are increasingly common, especially Mycobacterium avium complex. New treatments improve outcomes but require careful monitoring due to potential toxicities and drug interactions.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pulmonology

Background:

  • Nontuberculous mycobacteria (NTM) are increasingly recognized as significant clinical pathogens.
  • Mycobacterium avium complex (MAC) causes disseminated disease in AIDS patients and chronic lung disease in non-AIDS patients.
  • Traditional NTM treatments were often difficult and frustrating.

Purpose of the Study:

  • To highlight the growing clinical importance of NTM infections.
  • To discuss the impact of new antimicrobial agents on NTM treatment outcomes.
  • To emphasize the need for clinician awareness regarding NTM pathogenicity and treatment.

Main Methods:

  • Review of current literature on NTM epidemiology and treatment.
  • Analysis of the efficacy and toxicity profiles of new antimicrobial agents.

Related Experiment Videos

  • Discussion of clinical management strategies for NTM infections.

    • Main Results:

    • New agents like clarithromycin, azithromycin, and rifabutin have improved outcomes for some NTM infections.
    • Novel therapeutic regimens can cause severe toxicities and drug interactions.
    • Careful patient monitoring is crucial during treatment for MAC disease.

    Conclusions:

    • Clinicians must be prepared to identify and manage NTM infections with increasing frequency.
    • Knowledge of NTM species pathogenicity and appropriate therapies is essential.
    • Effective management of NTM infections requires understanding both treatment benefits and risks.